An option to Elixirgen's mutation-agnostic mRNA candidate could boost Nippon Shinyaku's DMD pipeline ahead of a patent expiry for one of its other top products.
An option to Elixirgen's mutation-agnostic mRNA candidate could boost Nippon Shinyaku's DMD pipeline ahead of a patent expiry for one of its other top products.